EBITDA: Income before interest, taxes, depreciation and amortization.
VistaGen Therapeutics, Inc. (VTGN) had EBITDA of $-19.63M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.30M |
|
$-18.90M |
|
-- |
|
$0.30M |
|
$19.85M |
|
$-19.55M |
|
$0.65M |
|
$-18.90M |
|
$-18.90M |
|
$-18.90M |
|
$-18.90M |
|
$-18.90M |
|
$-18.90M |
|
$-19.55M |
|
|
EBITDA |
$-19.63M |
42.23M |
|
42.23M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$63.24M |
|
$0.48M |
|
$1.81M |
|
$65.06M |
|
$13.53M |
|
-- |
|
$0.61M |
|
$14.14M |
|
$50.92M |
|
$50.92M |
|
$50.92M |
|
39.62M |
|
| Cash Flow Statement Financials | |
$-50.24M |
|
$-0.78M |
|
$31.25M |
|
$67.13M |
|
$47.37M |
|
$-19.76M |
|
$3.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.67 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
100.00% |
|
-6450.82% |
|
-6450.82% |
|
-- |
|
-6237.29% |
|
-6237.29% |
|
$-50.39M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-37.12% |
|
-37.12% |
|
-29.05% |
|
-37.12% |
|
$1.28 |
|
$-1.19 |
|
$-1.19 |
|